Mice with established type 2 diabetes received Cerebrolysin via intraperitoneal injection for 10 consecutive days
Clinician oversight Because SLU-PP-332 has no human safety profile, any research planning that involves human exposure should be done under qualified clinician oversight
Administered by licensed medical professionals: Delivered in a clinical setting by trained staff, ensuring both safety and proper technique
PMCID: PMC6770791 Giunta C, Elioglu NH, Albrecht B, Eich G, Chambaz C, Janecke AR, Yeowell H, Weis M, Eyre DR, Kraenzlin M, Steinmann B
Blood work including inflammatory markers (CRP, ESR), cytokine panels, and immune cell subsets can provide deeper insight into whether the protocol is modulating the underlying immune dysfunction